



## (51) International Patent Classification:

*C07D 213/61* (2006.01) *A61K 31/4418* (2006.01)  
*C07C 311/20* (2006.01) *A61P 29/00* (2006.01)  
*A61K 31/18* (2006.01)

## (21) International Application Number:

PCT/GB2014/051921

## (22) International Filing Date:

24 June 2014 (24.06.2014)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

1311361.8 26 June 2013 (26.06.2013) GB

(71) Applicant: **PIMCO 2664 LIMITED** [GB/GB]; 24  
 Cornhill, London Greater London EC3V 3ND (GB).

(72) Inventors: **PATEL, Lisa**; Modern Biosciences plc, 24  
 Cornhill, London Greater London EC3V 3ND (GB).  
**SMITH, Stephen Allan**; Stort MedChem Consulting, The  
 Courtyard, The Old Monastery, Windhill, Bishops Stortford  
 Essex CM23 2PE (GB). **GREIG, Iain Robert**; Institute of  
 Medical Sciences, University of Aberdeen, Foresterhill,  
 Aberdeen Aberdeenshire AB25 2ZD (GB). **WILLIAMS,  
 Samuel Cameron**; Modern Biosciences plc, 24 Cornhill,  
 London Greater London EC3V 3ND (GB).

(74) Agents: **WYTENBURG, Wilhelmus** et al.; Mewburn Ellis  
 LLP, 33 Gutter Lane, London, Greater London EC2V 8AS  
 (GB).

(81) Designated States (unless otherwise indicated, for every  
 kind of national protection available): AE, AG, AL, AM,  
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,  
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,  
 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,  
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,  
 ZW.

(84) Designated States (unless otherwise indicated, for every  
 kind of regional protection available): ARIPO (BW, GH,  
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,  
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
 KM, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

## Published:

— with international search report (Art. 21(3))

(54) Title: N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE

(57) Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and / or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitis, such as Behçet's disease. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.



WO 2014/207445 A1